Prostate Biopsy News and Research

RSS

The prostate is a small gland that wraps around the urethra, at the base of the urinary bladder. It produces semen, the fluid vehicle of spermatozoa. A biopsy of the prostate is a procedure in which a small sample of prostate tissue is removed in order to examine it, usually in search for signs of malignant transformation of prostate cells.

AUA clarifes recommendations on prostate cancer testing with PSA test and DRE

The American Urological Association (AUA) is aware of recent news reports disparaging prostate cancer testing. We are concerned that these reports are causing significant confusion for patients and we wish to clarify our recommendations on prostate cancer testing with the prostate-specific antigen (PSA) test and digital rectal exam (DRE). The AUA strongly supports early prostate cancer detection and feels it is in a man's best interest to consider being tested for prostate cancer.

4 Nov 2009

Fifth SEEM anniversary meeting to be held in Belgrade

On 9 and 10 October the anniversary South Eastern European Meeting (SEEM) will be held in the Yugoslav Drama Theatre (Jugoslovensko Dramsko Pozoriste) in Belgrade (RS). Professor Michael Marberger (Vienna, AT), chairman of the Regional Office of the European Association of Urology: "For the 5th time the SEEM will provide a platform where new experimental and clinical work from the region is presented to an international audience".

5 Oct 2009

Educational events for physicians who diagnose and treat prostate cancer

iCAD, Inc., an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today announces a series of educational events designed for radiologists, urologists, oncologists, radiation oncologists, surgeons, technologists and other referring physicians who diagnose and treat patients with prostate cancer.

17 Sep 2009

Diagnocure reports third-quarter fiscal 2009 results

DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced revenue of $396,468 and a net loss of $4,034,364 or $0.09 per share for the third quarter ending July 31, 2009.

17 Sep 2009

Third-quarter fiscal 2009 results announced by DiagnoCure

15 Sep 2009

Gen-Probe commences its PROGENSA PCA3 assay clinical trial

Gen-Probe Incorporated announced today that the Company has begun a clinical trial intended to secure U.S. regulatory approval of its PROGENSA(R) PCA3 assay, a new molecular test that may help determine the need for a repeat prostate biopsy.

28 Aug 2009

Gen-Probe commences clinical study to secure U.S. approval of the PROGENSA PCA3 assay

DiagnoCure Inc. (TSX: CUR) announced that Gen-Probe, Inc. (NASDAQ: GPRO), its partner for the development and commercialization of the PCA3 prostate cancer test, has confirmed today the beginning of a U.S. clinical study intended to secure U.S. regulatory approval of the PROGENSA(R) PCA3 assay, a new molecular test that may help determine the need for a repeat prostate biopsy.

28 Aug 2009

Study finds few patients die from prostate cancer within 15 years of radical prostatectomy

Investigators at Memorial Sloan-Kettering Cancer Center (MSKCC), along with collaborating teams at the Cleveland Clinic and the University of Michigan, have completed the first large- scale, multi-institutional study of prostate cancer death after standard treatment to remove the prostate since PSA screening has become widely used as a method to screen for the disease.

28 Jul 2009

Statins may benefit men with prostate cancer, erectile dysfunction or lower urinary tract symptoms

Several new studies presented at the American Urological Association's (AUA) 104th Annual Scientific Meeting suggest that the use of statins - commonly prescribed to lower cholesterol - may benefit men with prostate cancer, erectile dysfunction or lower urinary tract symptoms (LUTS).

26 Apr 2009

PSA levels accurately predict prostate cancer risk in African-American men

PSA levels appear to be more predictive of three year prostate cancer risk in African-American men compared with Caucasian men with a family history of prostate cancer, according to a paper published in Cancer Prevention Research, a journal of the American Association for Cancer Research.

24 Feb 2009

Prostate cancer discovered in 40% of men who test negative for the disease

Forty percent of men with prostate cancer may not even know they have it, according to a new research study by the Prostate Cancer Foundation of Chicago.

16 Dec 2008

Link between prostate inflammation and lower urinary tract symptoms

In the December issue of European Urology ( http://www.elsevier.com/locate/eururo ) Dr. Curtis Nickel and associates report on the evidence of a relationship between prostate inflammation and lower urinary tract symptoms (LUTS) in men enrolled in the REDUCE trial.

16 Nov 2008

Relationship between prostate inflammation and lower urinary tract symptoms evident

In the December issue of European Urology Dr. Curtis Nickel and associates report on the evidence of a relationship between prostate inflammation and lower urinary tract symptoms (LUTS) in men enrolled in the REDUCE trial.

13 Nov 2008

Monitoring blood flow helps improve prostate biopsies

Using a special ultrasound technique to spot areas of blood flow in the prostate gland may substantially reduce the number of unnecessary biopsies, according to a new study by urologists and radiologists at the Jefferson Prostate Diagnostic Center and the Kimmel Cancer Center at Jefferson in Philadelphia.

26 May 2008

Scientists cast doubt on value of screening for prostate cancer

Even though deaths from prostate cancer death have fallen in the U.S. since screening became more common, new research is suggesting that this does not justify the need for such tests.

17 Apr 2008

New study confirms that PROGENSA PCA3 can improve accuracy of prostate cancer diagnosis

New clinical data from a study of 570 men published in the peer-reviewed Journal of Urology support the use of PROGENSA PCA3 as a tool for diagnosing prostate cancer. The study confirms that PROGENSA PCA3, the world's first gene-based urine test to help detect prostate cancer, can provide clinicians with valuable information that helps guide diagnosis.

20 Mar 2008

Biopsy techniques have made PSA test less predictive

Prostate specific antigen (PSA) levels typically have correlated with prostate biopsy results in the detection of prostate cancer, but that correlation no longer exists for men with a normal prostate exam, according to a new study published in the April 15, 2008 issue of CANCER, a peer-reviewed journal of the American Cancer Society.

11 Mar 2008

Revelation of new genes linked to prostate cancer could single out high risk men

The discovery by researchers of at least ten new genes associated with prostate cancer could in future be used to accurately identify high-risk men.

11 Feb 2008

Henry Ford Hospital expands research on gene and radiation therapy for prostate cancer

Henry Ford Hospital is embarking on an expanded major clinical trial involving the use of gene therapy in combination with radiation therapy, to determine if the combined treatment is more effective than radiation therapy alone for patients with intermediate risk prostate cancer.

7 Feb 2008

Experimental biomarker test beats PSA in detecting prostate cancer

An experimental biomarker test developed by researchers at the University of Michigan more accurately detects prostate cancer than any other screening method currently in use, according to a study published in the February 1 issue of Cancer Research, a journal of the American Association for Cancer Research.

5 Feb 2008